MRI Risk Maps for Prostate Cancer Diagnosis Using Targeted Biopsy
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexMale
Age18+
SponsorUniversity of Chicago
About this trial
Doctors leading this study hope to learn about a software that researchers at the University of Chicago have developed to help analyze radiographic images (different techniques for taking images that allow doctors to visualize the body's internal structures) of the prostate. Participation in this research will last about 12 months. There is a one-time MRI and 1-2 biopsies and then the investigator would like to follow the participant's progress.
Eligibility criteria
Qualifiers
Patients with known or suspected prostate cancer who have been referred for a diagnostic magnetic resonance imaging (MRI) exam of the prostate, to be followed by an MRI-guided fusion biopsy of the prostate.
Voluntary written informed consent before the MRI examination.
Disqualifiers
Subjects incapable of giving informed written consent.
Subjects who cannot adhere to the experimental protocols for any reason, or have an inability to communicate with the researcher;
Subjects with psychiatric disorders that affect their ability to consent for themselves will be excluded and not the entire population of patients with psychiatric disorders.
Prisoners.
Trial design
Treatments tested in this trial
- Risk Map Decision Support System (DSS).
- Magnetic Resonance Imaging (MRI)
- Magnetic Resonance Imaging (MRI) Guided Biopsy
Treatment groups
180 Participants
are divided into 1 treatment groupSponsors and collaborators
University of Chicago
Lead sponsor
National Cancer Institute (NCI)
Collaborator
Source ClinicalTrials.gov